SCHEMBL2407173

SCHEMBL2407173

O=C(O)c1cccc(-c2cc(Cl)cc([N+](=O)[O-])c2O)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 4/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
POLB P06746 2/20 0.43
NSD2 O96028 1/20 0.43
PLA2G1B P04054 1/20 0.43
PLCG1 P19174 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
KDM4E B2RXH2 4/20 0.41
MAPT P10636 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 2/20 0.41
GPR35 Q9HC97 2/20 0.40
DUSP3 P51452 1/20 0.40
TTR P02766 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ACMSD Q8TDX5 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2410304 0.85 GPR35 (0.49) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL2405659 0.79 PTGER1 (0.47) PTGER1KDM4ETDP1ALOX15TSHR
SCHEMBL2406744 0.75 KDM4C (0.46) MEN1KMT2APOLBNSD2PLA2G1B
SCHEMBL29386074 0.74 ERN1 (0.57) MAPTDUSP3TTRCRHBPCRHR2
SCHEMBL2404465 0.74 ERN1 (0.57) MAPTDUSP3TTRCRHBPCRHR2
SCHEMBL2405617 0.74 PTGER1 (0.56) PTGER1MEN1KMT2AKDM4EMAPT
Niclofolan SCHEMBL29385615 0.74 GPR35 (0.57) MEN1KMT2APOLBKDM4EMAPT
Niclofolan SCHEMBL1498232 0.74 GPR35 (0.57) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL4348393 0.72 ERN1 (0.54) MEN1KMT2APOLBNSD2PLA2G1B
SCHEMBL5110264 0.72 AKR1C4 (0.56) MEN1KMT2APOLBNSD2PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101343250-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-09-21 CN claimed
CN-101343250-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN claimed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
CN-101343251-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-11-09 CN disclosed
CN-101343250-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-09-21 CN disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PTGER1 636/4885MEN1 229/4885KMT2A 1838/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PTGER1 636/4885MEN1 229/4885KMT2A 1838/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PTGER1 636/4885MEN1 229/4885KMT2A 1838/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PTGER1 636/4885MEN1 229/4885KMT2A 1838/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PTGER1 636/4885MEN1 229/4885KMT2A 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.